New Blood Test Helps Personalize Patients' Treatment
Posted on: Sunday, 30 October 2005, 03:01 CST
By Anonymous
The US Food and Drug Administration (FDA) has I cleared the use of a new blood test that can help physicians make personalized medication treatment decisions for some patients, according to an Aug 22, 2005, news release from the FDA. The UGTlAl molecular assay detects genetic variations that may affect how certain medications are metabolized and cleared by the body. Physicians can use this information to help determine the right medication dosage for individual patients and minimize harmful medication reactions.
The assay detects variations in UGTlAl, the gene that produces the UDP-glucuronosyltransferase enzyme. This enzyme is active in the metabolism of certain medications, such as irinotecan, a medication used in colorectal cancer treatment. Variations in the UGTlAl gene can influence a patient's ability to break down irinotecan, which can lead to increased blood Levels of the medication and a higher risk of side effects.
The assay was studied in 66 patients who were receiving irinotecan therapy. The study showed that people with one type of genetic variation have a risk of experiencing irinotecan toxicity that is five times greater than for those who do not have the genetic variation.
The molecular assay is intended to help physicians make individualized patient treatment decisions. It is not a substitute for a physician's judgment or clinical experience.
FDA Clears Genetic Test That Advances Personalized Medicine: Test Helps Determine Safety of Drug Therapy (news release, Rockville, Md: US Food and Drug Administration, Aug 22, 2005) http://www.fda.gov/ bbs/topics /NEWS/2005/NEW01220.html (accessed 6 Sept 2005).
Copyright Association of Operating Room Nurses, Inc. Oct 2005
Source: Association of Operating Room Nurses. AORN Journal
Related Articles
- EPIX Pharmaceuticals Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimer's Disease Patient
- FDA Approves Two Hologic HPV Tests
- Cancer Patients, Physicians, Community Voice Support for Proton Therapy Center
- Quebec Hospital Asks Patients to Redo Tests Whose Results May Be Faulty
- FDA Approves Norditropin(R)for Treatment of Short Stature Associated With a Rare Genetic Disorder
- New Industry Surveys Reveal Pharmaceutical Marketing Focus on Patient-Physician Communications and Physician Support For Patient Feedback
- Patients & Physicians, Inc. Announces Name Change to Flagship Global Health, Inc.; New Trading Symbol is FGHH
- FDA Approves Lead Poisoning Blood Test
- Understand the Dynamics of the Patient-Physician Relationship and the Market Trends Driving Its Evolution
- Patients With Treatment-Resistant Schizophrenia Get Good News Today at American Psychiatric Association Meeting in Atlanta
 |
 |
User Comments (0)
RSS Feeds